Takeda Moves Incontinence Candidate To New Venture
This article was originally published in PharmAsia News
Takeda has licensed a non-core pipeline asset in the urology field to a new venture co-founded by its former top R&D executive.
You may also be interested in...
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.